Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation

Shares of Amgen, Inc. (NASDAQ:AMGN), which are up almost 16% this year, were trending high in the early afternoon hours, gaining nearly 4% after a day that saw them topple following negative study results. It appears as though investors are now less concerned about the failed trail because the company said the positive results obtained earlier this month would be sufficient to support submissions for regulatory approvals around the world. On CNBC, Yaron Werber, senior biotech analysts at Citi Investment Research, weighed in on the failed study and what lies ahead for the company.

Amgen, Inc. (NASDAQ:AMGN)

Amgen, Inc. (NASDAQ:AMGN) reported that a study of its drug Kyprolis, for a type of blood cancer, failed to help patients live longer compared to the standard care. The study focused on patients with an advanced case of the blood cancer condition known as multiple myeloma. The drug is approved in the U.S., but the company needed survival evidence to obtain approval in Europe.

Coming on to the case of Amgen, Inc. (NASDAQ:AMGN) and the failure of Kyprolis to improve survival rates, Werber said all is not lost for the company because it already has study results that are good enough for approval.

“This is one of the main reasons why Amgen quite earned it. To put it into perspective, they’ve had another study that was successful recently for the drug that will get approved. But overall, if you look at the profile of this drug Kyrolis  myeloma, which is a blood cancer, the overall profile is probably not quite with originally expected, and we think maybe numbers are going to come down,” he said.

He also talked about Amgen, Inc. (NASDAQ:AMGN)’s journey into developing treatment for myeloma and the marketing opportunity for Kyrolis. He noted that the market is there, but the challenge is that patients keep advancing to better drugs that can keep them alive.

“The market is sizable and continues to grow, and as you know, unfortunately, patients with cancer die, and they always progress from one drug to the next [...],” said Werber.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!